Pimozide: use in Tourette's syndrome

Area of Science:

• Neurology
• Pharmacology

Background:

• Tourette's syndrome (TS) involves involuntary motor and vocal tics, often linked to neurochemical imbalances.
• Pimozide, an orphan drug, has gained FDA approval for TS treatment.
• Pimozide exhibits distinct receptor selectivity compared to haloperidol, the established TS therapeutic.

Purpose of the Study:

• To evaluate the efficacy and safety of pimozide in Tourette's syndrome treatment.
• To compare pimozide's therapeutic profile with that of haloperidol.
• To define the optimal role of pimozide in the management of TS.

Main Methods:

• Clinical trials were conducted to assess patient responses to pimozide.
• Adverse event profiles, including severe side effects like tardive dyskinesia and cardiovascular toxicity, were monitored.
• Pharmacokinetic properties, such as pimozide's long half-life enabling once-daily dosing, were considered.

Main Results:

• Pimozide demonstrated positive responses in a significant number of TS patients.
• Overall superiority of pimozide over haloperidol was not established in clinical trials.
• A notable percentage of patients experienced side effects, with potential for severe adverse events with increased dosage or duration.

Conclusions:

• Pimozide offers a treatment option for Tourette's syndrome, particularly for patients unresponsive to or intolerant of haloperidol.
• The use of pimozide necessitates careful consideration of its side effect profile and potential risks.
• Pimozide's long half-life supports convenient once-daily administration in clinical practice.